Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial

Figures

• 

  Figure 1. (A) N-terminal pro B-type natriuretic peptide, (B) high-sensitivity cardiac troponin T, (C) systolic blood pressure, and (D) heart rate: their independent contributions according to fifths of their distributions to risk of the primary outcome (a composite of time-to-first heart failure hospitalization or cardiovascular death). CI, confidence interval; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro B-type natriuretic peptide.

• 

  Figure 2. Observed vs. predicted events by tenths of the risk score distribution. Hosmer–Lemeshow goodness-of-fit test P = 0.473 for the primary outcome (A) and P = 0.053 for all-cause mortality (B), indicating adequate calibration. CI, confidence interval.

• 

  Figure 3. Hazard ratios and rate differences for the primary outcome (empagliflozin vs. placebo) according to thirds of the risk score distribution. CI, confidence interval; HR, hazard ratio.

• 

  Figure 4. Mortality risks for N-terminal pro B-type natriuretic peptide (A) and high-sensitivity cardiac troponin T (B): their independent contributions according to fifths of their distribution. CI, confidence interval; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro B-type natriuretic peptide.

• 

  Figure 5. Incidence rates per 100 patient-years of (A) the primary outcome and (B) all-cause death for patients simultaneously grouped in thirds of N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin T. hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro B-type natriuretic peptide